Product Development

Following significant Phase 2 findings, the FDA is supportive of a Phase 3 pivotal study to determine the effectiveness of NP002 at reducing falls

Phase 2 Study
The gold standard of treatment for Parkinson’s Disease (PD) is Levodopa (L-DOPA), a drug that causes movement disorders and falls. NP002 was studied in a Phase 2, 12-center, double-blind, randomized study of 65 PD patients with movement disorders and falling. The target indication for NP002 was the reduction of falls in patients diagnosed with idiopathic Parkinson’s Disease, who were on L-DOPA therapy and experienced recurrent falls.
Favorable Efficacy and Safety Profile

NP002 is a central cholinergic antagonist. In Phase 2, it achieved statistical significance in reducing falls, improving ambulation, and improving postural stability when compared to placebo. NP002 was well tolerated with no serious adverse events reported.


We’re seeking partners

We are currently seeking partners to support the development and commercialization of NP002.